This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
4 Aug 2016

FDA approves Flonase Sensimist Allergy Relief

Another Rx-to-OTC Switch from GSK Consumer Healthcare to help allergy sufferers find more complete relief.

GSK Consumer Healthcare has announced that the FDA has approved Flonase Sensimist Allergy Relief (fluticasone furoate, 27.5 mcg spray) as an over-the-counter (OTC) treatment for symptoms associated with seasonal and perennial allergies. Previously available by prescription as Veramyst, Flonase Sensimist is the latest Rx-to-OTC switch from GSK.

Flonase Sensimist helps block six allergic substances, providing non-drowsy, 24-hour relief of both nose- and eye-related allergy symptoms such as itchy, watery eyes, nasal congestion, runny nose, itchy nose and sneezing.

"There are roughly 50 million people in the US who suffer from allergies, and, as a category leader, GSK continues to innovate to satisfy the needs of all allergy sufferers," said Amardeep Kahlon, Director of Marketing. "In the case of Flonase Sensimist, GSK is proud to offer an additional treatment option that not only provides more complete allergy symptom relief but also suits specific consumer preferences."

Additional key features of Flonase Sensimist include

  • Nasal allergy relief indicated for adults and children ages 2 and older
  • Scent-free
  • Alcohol-free
  • Little or no drip
  • Flonase Sensimist will be nationally available OTC in early 2017.

    Related News